These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 10855790)

  • 1. Targeting vascular endothelial growth factor (VEGF) for anti-tumor therapy, by anti-VEGF neutralizing monoclonal antibodies or by VEGF receptor tyrosine-kinase inhibitors.
    Schlaeppi JM; Wood JM
    Cancer Metastasis Rev; 1999; 18(4):473-81. PubMed ID: 10855790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The pivotal role of VEGF in tumor angiogenesis: molecular facts and therapeutic opportunities.
    Siemeister G; Martiny-Baron G; Marmé D
    Cancer Metastasis Rev; 1998 Jun; 17(2):241-8. PubMed ID: 9770121
    [No Abstract]   [Full Text] [Related]  

  • 3. The role of vascular endothelial growth factor in angiogenesis.
    Ferrara N; Gerber HP
    Acta Haematol; 2001; 106(4):148-56. PubMed ID: 11815711
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vascular permeability factor/vascular endothelial growth factor: a multifunctional angiogenic cytokine.
    Brown LF; Detmar M; Claffey K; Nagy JA; Feng D; Dvorak AM; Dvorak HF
    EXS; 1997; 79():233-69. PubMed ID: 9002222
    [TBL] [Abstract][Full Text] [Related]  

  • 5. VEGF receptor signaling in tumor angiogenesis.
    McMahon G
    Oncologist; 2000; 5 Suppl 1():3-10. PubMed ID: 10804084
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical development of angiogenesis inhibitors to vascular endothelial growth factor and its receptors as cancer therapeutics.
    Zhu Z; Bohlen P; Witte L
    Curr Cancer Drug Targets; 2002 Jun; 2(2):135-56. PubMed ID: 12188915
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of tumor growth and metastasis by targeting tumor-associated angiogenesis with antagonists to the receptors of vascular endothelial growth factor.
    Zhu Z; Witte L
    Invest New Drugs; 1999; 17(3):195-212. PubMed ID: 10665474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation.
    Yano S; Herbst RS; Shinohara H; Knighton B; Bucana CD; Killion JJ; Wood J; Fidler IJ
    Clin Cancer Res; 2000 Mar; 6(3):957-65. PubMed ID: 10741721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Anti-angiogenic reagents].
    Shibuya M
    Tanpakushitsu Kakusan Koso; 2000 Apr; 45(6 Suppl):1182-7. PubMed ID: 10771693
    [No Abstract]   [Full Text] [Related]  

  • 10. Targeting vascular endothelial growth factor blockade: ascites and pleural effusion formation.
    Verheul HM; Hoekman K; Jorna AS; Smit EF; Pinedo HM
    Oncologist; 2000; 5 Suppl 1():45-50. PubMed ID: 10804091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy.
    Wood JM
    Medicina (B Aires); 2000; 60 Suppl 2():41-7. PubMed ID: 11188930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vascular endothelial growth factor (VEGF) receptor-2 antagonists inhibit VEGF- and basic fibroblast growth factor-induced angiogenesis in vivo and in vitro.
    Tille JC; Wood J; Mandriota SJ; Schnell C; Ferrari S; Mestan J; Zhu Z; Witte L; Pepper MS
    J Pharmacol Exp Ther; 2001 Dec; 299(3):1073-85. PubMed ID: 11714897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of vascular endothelial growth factor (VEGF) in AIDS-related Kaposi's sarcoma.
    Arastéh K; Hannah A
    Oncologist; 2000; 5 Suppl 1():28-31. PubMed ID: 10804088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vascular endothelial growth factor in human colon cancer: biology and therapeutic implications.
    Ellis LM; Takahashi Y; Liu W; Shaheen RM
    Oncologist; 2000; 5 Suppl 1():11-5. PubMed ID: 10804085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors.
    Petit AM; Rak J; Hung MC; Rockwell P; Goldstein N; Fendly B; Kerbel RS
    Am J Pathol; 1997 Dec; 151(6):1523-30. PubMed ID: 9403702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two independent mechanisms essential for tumor angiogenesis: inhibition of human melanoma xenograft growth by interfering with either the vascular endothelial growth factor receptor pathway or the Tie-2 pathway.
    Siemeister G; Schirner M; Weindel K; Reusch P; Menrad A; Marmé D; Martiny-Baron G
    Cancer Res; 1999 Jul; 59(13):3185-91. PubMed ID: 10397264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice.
    Brekken RA; Overholser JP; Stastny VA; Waltenberger J; Minna JD; Thorpe PE
    Cancer Res; 2000 Sep; 60(18):5117-24. PubMed ID: 11016638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monoclonal antibodies to vascular endothelial growth factor (VEGF) and the VEGF receptor, FLT-1, inhibit the growth of C6 glioma in a mouse xenograft.
    Stefanik DF; Fellows WK; Rizkalla LR; Rizkalla WM; Stefanik PP; Deleo AB; Welch WC
    J Neurooncol; 2001 Nov; 55(2):91-100. PubMed ID: 11817706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vascular endothelial growth factor and its receptors.
    Klagsbrun M; D'Amore PA
    Cytokine Growth Factor Rev; 1996 Oct; 7(3):259-70. PubMed ID: 8971481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vascular permeability factor/vascular endothelial growth factor-mediated signaling in mouse mesentery vascular endothelium.
    Mukhopadhyay D; Nagy JA; Manseau EJ; Dvorak HF
    Cancer Res; 1998 Mar; 58(6):1278-84. PubMed ID: 9515816
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.